Daiichi Sankyo Company, Limited · TSE:4568
Daiichi Sankyo — FY2017 Earnings Presentation
84 slides from Daiichi Sankyo's earnings presentation, Apr 27, 2018
Slide 1: Top Management Presentation: Financial Results for FY2017
Top Management Presentation Financial Results for FY2017 (April 1, 2017 – March 31, 2018) DAIICHI SANKYO CO., LTD Sunao Manabe President and COO April 27, 2018
Slide 2: Forward-Looking Statements
Forward-Looking Statements Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo’s future prospects. These forward looking statements were determined by Daiichi Sa
Slide 3: Agenda
Agenda FY2017 Financial Results Progress of 5-Year Business Plan FY2018 Consolidated Forecast 3
Slide 4: FY2017 Financial Results
Dalichi-Sankyo FY2017 Financial Results
Slide 5: Overview of FY2017 Results
Overview of FY2017 Results (Bn JPY) FY2016 Results FY2017 Results YoY +0.5% Revenue 955.1 960.2 +5.1 Cost of Sales 349.4 346.0 -3.4 SG&A Expenses 302.5 301.8 -0.6 R&D Expenses 214.3 236.0 +21.7 -14.2% Operating Profit 88.9 76.3 -12.6 Profit before Tax 87.8 81.0 -6.8 +12.7% Profit attributable to own
Slide 6: Revenue
Revenue Increased by 5.1 Bn JPY (Decreased by 8.9 Bn JPY excl. forex impact) (Bn JPY) FY2016 Results 955.1 Positive Factors Negative Factors Japan Japan (incl. vaccines, OTC) 38.5 Lixiana +20.3 Olmetec -24.8 Inavir +5.7 Daiichi Sankyo, Inc. (US) 69.2 Pralia +5.2 Daiichi Sankyo +26.5 Luitpold (US) 15
Slide 7: Operating Profit
Operating Profit Decreased by 12.6 Bn JPY (Decreased by 21.3 Bn JPY excl. forex impact and special items) FY2016 Results 88.9 増益 減益 (Bn JPY) Revenue +5.1 Revenue 5.1 incl. forex impact of +14.0 Cost of Sales 18.6 Cost of Sales +18.6 (Cost increased) Product mix due to impact of olmesartan LOE SG&A E
Slide 8: Special Items
Special Items (Bn JPY) FY2016 Results FY2017 Results YoY Restructuring costs in SC 3.6 Gain on sales of fixed assets -6.1 Cost of Sales Impairment loss (Vaccine) 20.6 Impairment loss (Intangible) 5.1 -25.2 Restructuring costs in EU 10.6 Restructuring costs in US 2.8 SG&A Expenses Impairment loss (Va
Slide 9: Profit Attributable to Owners of the Company
Profit Attributable to Owners of the Company Increased by 6.8 Bn JPY FY2016 Results 53.5 (Bn JPY) Financial Income/ -5.9 (Cost decreased) Operating Profit 12.6 Expenses etc. Improvement of forex gains/ losses Financial Income/ Expenses etc. 5.9 Income Taxes etc. -19.1 (Cost decreased) Income Taxes e
Slide 10: Revenue: Major Business Units (incl. Forex Impact)
Revenue: Major Business Units (incl. Forex Impact) (Bn JPY) FY2016 FY2017 vs. Forecast* YoY Results Results (%) Japan 506.6 540.0 +33.5 100.8% Daiichi Sankyo Healthcare 66.7 72.9 +6.2 102.7% Daiichi Sankyo Inc. 142.3 74.8 -67.5 106.8% Olmesartan 66.4 21.3 -45.0 118.5% Welchol 45.5 33.9 -11.6 102.8%
Slide 11: Revenue: Major Products in Japan
Revenue: Major Products in Japan (Bn JPY) FY2016 FY2017 vs. Forecast* YoY Results Results (%) Nexium ulcer treatment 84.0 86.5 +2.6 104.3% Alzheimer’s disease Memary treatment 46.9 48.6 +1.7 97.1% Olmetec antihypertensive agent 69.4 44.6 -24.8 94.9% Lixiana anticoagulant 25.0 45.3 +20.3 100.8% Loxon
Slide 12: Progress of 5-Year Business Plan
Progress of 5-Year Business Plan 12
Slide 13: Progress of 5-Year Business Plan
Progress of 5-Year Business Plan Grow Edoxaban Grow as No.1 Company in Japan Expand US Businesses Establish Oncology Business Continuously Generate Innovative Medicine Changing SOC (Standard of Care) Enhance Profit Generation Capabilities Shareholder Returns 13
Slide 14: Progress of 5-Year Business Plan
Progress of 5-Year Business Plan Grow Edoxaban Grow as No.1 Company in Japan Expand US Businesses Establish Oncology Business Continuously Generate Innovative Medicine Changing SOC (Standard of Care) Enhance Profit Generation Capabilities Shareholder Returns 14
Slide 15: Edoxaban: Target and Progress
Edoxaban: Target and Progress Expanding mainly in Japan, EU and Asia 120.0 Bn JPY (1 Bn USD) 105.0 Bn JPY 77.1 Bn JPY 37.3 Bn JPY 15.0 Bn JPY FY2015 FY2016 FY2017 FY2018 FY2020 Results Results Results Forecast 5-Year Business Plan Target 15
Slide 16: Global DOAC Market Sales
Global DOAC Market Sales Global DOAC market value was grown up to about $20 Bn (Bn JPY) (%) *1 *2 Currency Rate USD/JPY : 110 *1: Jan. 2013 – Dec. 2013 Copyright © 2018 IQVIA *2: Percentage of DOAC Days of Therapy (DOT) counts to total DOT of warfarin and DOAC Calculated based on MIDAS Sales Data 16
Slide 17: DOAC Market in Japan and Germany
DOAC Market in Japan and Germany Sales Japan Germany (Bn JPY) (Bn JPY) Currency Rate USD/JPY : 110 Copyright © 2018 IQVIA Calculated based on MIDAS Sales Data 17 Reprinted with permission
Slide 18: Lixiana: Growth in Japan (Sales)
Lixiana: Growth in Japan Sales As of FY2017 Q4, Lixiana increased its sales share to 25.4%. (%) 50 40 30 Lixiana Product A 20 25.4% Product B 10 Product C 0 Copyright © 2018 IQVIA. Calculated based on JPM FY2014 Q1 - FY2017 Q4 Reprinted with permission 18
Slide 19: Lixiana: Growth in Japan (Volume)
Lixiana: Growth in Japan Volume Lixiana has reached top Rxs share since Mar. 2017 in prescription number of new patients for AF+VTE. The share expanded to 41.6% in Mar 2018. 41.6% (%) (Mar. 2018) 40 35 30 25 20 15 10 5 0 Source :Medi-trend 19
Slide 20: Lixiana: Growth in Germany and South Korea
Lixiana : Sales Growth in Germany and South Korea Steady growth since launch Reached 3rd share in Germany and South Korea (%) Germany (%) South Korea 23.1% 12 24 10.5% 22 10 20 18 8 16 14 6 12 10 4 8 6 2 4 2 0 0 Jan-16 Jan-17 Jan-18 Mar-16 Jul-16 Sep-16 Mar-17 Nov-16 Jul-17 Sep-17 Nov-17 May-16 Ma
Slide 21: Growth in Each Country (Summary)
Growth in Each Country (Summary) Volume Edoxaban volume (DoT) % share of DOAC markets over time 25% 22.6% S. Korea 21.8% Japan 20% Germany 15% 11.4% 11.2% Taiwan 10.0% Belgium 10% 8.0% Italy 7.6% Spain 5% 2.1% UK 0.4% USA 0% Copyright © 2018 IQVIA. Calculated based on MIDAS Data 21 Reprinted with pe
Slide 22: Image for future growth
Image for future growth Countries launched by FY2016: Japan, US, Switzerland, UK, Germany, Ireland, Launch Strategy Netherlands, S. Korea, Italy, Spain, Taiwan, Launched and approved in over 20 countries Belgium, Hong Kong, Denmark, Hungary, Finland, Norway, Austria etc. Covered about 95% of DOAC ma
Slide 23: Edoxaban Life Cycle Management
Edoxaban Life Cycle Management Edoxaban Clinical Research Program 23
Slide 24: Edoxaban Life Cycle Management
Edoxaban Life Cycle Management Edoxaban Clinical Research Program Ongoing randomized controlled trials in various FY2017 Results clinical settings in AF and VTE Clinical Setting Primary Study Name (Comparator) Completion Following the positive opinion of European Cardioversion (enoxaparin/ Present
Slide 25: Edoxaban Life Cycle Management
Edoxaban Life Cycle Management Edoxaban Clinical Research Program Non-interventional studies and registries to generate real-world data FY2017 Results including completed, ongoing and future research Red: Update or new Study Name Clinical Setting Edoxaban Treatment in Patient enrollment is ongoing
Slide 26: Progress of 5-Year Business Plan
Progress of 5-Year Business Plan Grow Edoxaban Grow as No.1 Company in Japan Expand US Businesses Establish Oncology Business Continuously Generate Innovative Medicine Changing SOC (Standard of Care) Enhance Profit Generation Capabilities Shareholder Returns 26
Slide 27: Major Products in Japan: Target and Progress
Major Products in Japan: Target and Progress Major factors changed from original assumption Share Share No.1 No.1 Nexium: “Special expansion re-pricing” Memary: Slow down of growth 243.0 Bn JPY Efient: Delay of additional indication for brain area Ulcer treatment Alzheimer’s disease Nexium t
Slide 28: Innovative Business: Results in FY2017
Innovative Business:Results in FY2017 Sustain growth momentum built in FY2017 FY2017 Results Red: Update or new Continuous No.1 in Japanese Growth of launch & sales pharmaceutical Japan No.1 growth of own Business market (FY2016) products NDA submissions for Mirogabalin for Top class PNP and Sal
Slide 29: For Continuous Launch of Own Products
For Continuous launch of Own Products Mirogabalin NDA submission in Feb. 2018 For peripheral neuropathic pain (PNP) PNP is caused by damage or functional abnormality of peripheral nerves due to various causes. Typical PNPs are diabetic PNP (DPNP*) and postherpetic neuralgia (PHN*). Esaxere
Slide 30: Reorganization of KDSV
Reorganization of KDSV KDSV’s manufacturing will be transferred to newly established Daiichi Sankyo Biotech Leveraging expertise and technology related to biologics which KDSV has experienced, Daiichi Sankyo Biotech will manufacture not only vaccine but biologics As of Apr. 2019 As of Apr. 2018 (Pla
Slide 31: Position of Daiichi Sankyo Biotech
Position of Daiichi Sankyo Biotech Daiichi Sankyo Biotech: Improving stable production and quality level by strengthening GMP system as one of Daiichi Sankyo Supply Chain Unit Daiichi Sankyo Supply Chain Unit New company Daiichi Sankyo Overseas Daiichi Sankyo Daiichi Sankyo Chemical Supply Chain Pro
Slide 32: Progress of 5-Year Business Plan
Progress of 5-Year Business Plan Grow Edoxaban Grow as No.1 Company in Japan Expand US Businesses Establish Oncology Business Continuously Generate Innovative Medicine Changing SOC (Standard of Care) Enhance Profit Generation Capabilities Shareholder Returns 32
Slide 33: Pain Business of Daiichi Sankyo, Inc.: Target and Progress
Pain Business of Daiichi Sankyo, Inc. : Target and Progress 100.0 Bn JPY Major factors happened in FY2017 Returned development and commercialization right of CL-108 to Charleston Labs, Inc. The Ph3 trials of Mirogabalin for fibromyalgia failed Revisit pain business of Daiichi Sankyo, Inc. 4.2 5.
Slide 34: Revisit pain business of Daiichi Sankyo, Inc.
Revisit pain business of Daiichi Sankyo, Inc. We take the complex issues surrounding the US opioid market very seriously. We are committed to marketing our three pain care medicines, Movantik, MorphaBond ER and RoxyBond, in a responsible manner while responding to patient needs. Launched October
Slide 35: Reorganization of US Commercial Organization
Reorganization of US Commercial Organization FY2017 Results We reorganized US commercial organization to align with current portfolio and prepare for upcoming oncology pipeline. (Reduced headcount by approximately 280 employees, one fourth in U.S. commercial organization including sales force and ho
Slide 36: Luitpold Business: Target and Progress
Luitpold Business: Target and Progress Realize rapid and sustainable growth with Iron Franchise and Generic injectable franchise 1,250 Mn USD (150.0 Bn JPY) 1,000 Mn USD (110.0 Bn JPY) 951 Mn USD (105.4 Bn JPY) 812 Mn USD (88.1 Bn JPY) 758 Mn USD (91.0 Bn JPY) 355 310 Mn USD Mn USD (39.0 221 (34.3 B
Slide 37: Growth of Iron Franchise
Growth of Iron Franchise US IV Iron Market ($M) (includes dialysis) $900 $853 Maintain Venofer and $762 $800 Injectafer Market Leadership $700 $658 $600 32.2% 25.8% $500 38.2% 14.1% 22.8% 30.8% $400 $300 $200 50.4% 44.8% 37.9% $100 $ 56.6% 48.2% 42.5% Sales $ Sales $ Sales $ MAT Feb 2016 MAT Feb 201
Slide 38: Value Maximization for Injectafer
Value Maximization for Injectafer Integrated sales team (Daiichi Sankyo, Inc. and Luitpold) Accelerated sales growth (continue double digit growth) Sales promotion is expanding into new area OBGYN Cardiologist Gastro Nephrologist Oncologist HEART-FID (Ph3 study)* For patients in heart fail
Slide 39: Growth of Generic Injectable Franchise
Growth of Generic Injectable Franchise Increase of product by continuous launch of new products (Number of products) 7 NDA submissions Submission and Launch FY2017 Results 6 製品 Launches 3 NDA submissions, 9 ANDA submissions ポートフォリオ 3 NDA submissions 5 Launches 9 ANDA submissions の充実 FY2018 Targe
Slide 40: Progress of 5-Year Business Plan
Progress of 5-Year Business Plan Grow Edoxaban Grow as No.1 Company in Japan Expand US Businesses Establish Oncology Business Continuously Generate Innovative Medicine Changing SOC (Standard of Care) Enhance Profit Generation Capabilities Shareholder Returns 40
Slide 41: Establish Oncology Business: 5-Year Business Plan
Establish Oncology Business: 5-Year Business Plan Steadily drive development of early-stage pipeline Going Accelerate oncology R&D through new R&D organization well By FY2025 revenue approx. 300.0 Bn JPY By FY2020 revenue over 40.0 Bn JPY 2015 2017 2020 2025 41
Slide 42: Consolidating Internal Structure for Launch
Consolidating Internal Structure for Launch Restructured organization and hired top oncology talent to accelerate development and launch Global Oncology Marketing Accelerate Positioning assets to meet customers’ Development need through competitive Shift resources to differentiation achieve “7 in 8”
Slide 43: Shifting Internal Resources to Oncology
Shifting Internal Resources to Oncology Oncology SM: Specialty Medicine* 39% 50% Research 61% 50% 2017 2018 47% 70% Development 53% 30% 2017 2018 Development budget allocation is done ahead of schedule *Other than oncology. Including CVM, pain, CNS 43 disease, heart-kidney disease, and rare diseases
Slide 44: Restructuring to Strengthen Oncology
Restructuring to Strengthen Oncology ① Oncology regulatory placed under global oncology development function (SM* regulatory under SM development) Regulatory focusing only on oncology provides acceleration of oncology development ② Consolidate CVM** and Other Clinical functions to one function A
Slide 45: Cancer Enterprise 2025 Vision
Cancer Enterprise 2025 Vision By 2025, Cancer Enterprise will be a leading world-class science organization built on 3 pillars aiming to deliver 7 valuable, distinct NME*s Establish Investigative ADC and AML franchises and Breakthrough Science as 3 pillars *NME: new molecular entity Breakthrough A
Slide 46: DS-8201: FY2017 Progress
ADC DS-8201: FY2017 Progress FY2017 Q1 FY2017 Q2 FY2017 Q3 FY2017 Q4 FY2018 Q1 Multiple Multiple Tumors Ph1 Tumors Global Jun, ASCO Sep, ESMO Dec, SABCS Jan, ASCO GI BC/GC CRC/NSCLC BC GC HER2+ mBreast Post T-DM1 Breast Oct, FSD Pivotal Ph2 (DESTINY-Breast01) Global Aug, US FDA Breakthrough Therapy
Slide 47: ADC Franchise: FY2017 Progress
ADC ADC Franchise: FY2017 Progress FY2017 Q1 FY2017 Q2 FY2017 Q3 FY2017 Q4 FY2018 Q1 HER3+ Breast Ph1/2 Jun, ASCO U3-1402 Study design HER3-ADC Breast NSCLC Apr, AACR Jan, FSD EGFRm NSCLC Ph1 Pharmacology data DS-1062 TROP2-ADC Feb, FSD NSCLC Ph1 Solid tumor NSCLC Oct, Option contract for developing
Slide 48: AML Franchise: FY2017 Progress
AML AML Franchise: FY2017 Progress FY2017 Q1 FY2017 Q2 FY2017 Q3 FY2017 Q4 FY2018 Q1 QuANTUM-R Study (FLT3-ITD AML Relapsed/Refractory 2nd line) Ph3 Apr, Aug, Quizartinib interim analysis Enrollment Complete Q1, TLR FLT3 inhibitor AML QuANTUM-First study (FLT3-ITD AML 1st line) Ph3 Sep, ESMO Study d
Slide 49: DS-3032 + Azacitidine Combo Study
AML DS-3032 + Azacitidine Combo Study Non-clinical Study Result DS-3032+Azacitidine human AML Xenograft model 50 mg/kg DS-3032b + 4 mg/kg Azacitidine Hypothesis: Combination of drugs Enhancement of additive efficacy by the with broad activity spectrum will combination is indicated improve efficacy 3
Slide 50: Breakthrough Science: FY2017 Progress
BTS Breakthrough Science: FY2017 Progress FY2017 Q1 FY2017 Q2 FY2017 Q3 FY2017 Q4 FY2018 Q1 Pexidartinib CSF-1/KIT/FLT3 inhibitor ENLIVEN TGCT Ph3 TGCT Oct, TLR DS-1647 Investigator Initiated Study Ph2 G47Δ virus Glioblastoma Jul, JP Orphan Drug Designation DS-1205 EGFRm NSCLC AXL Sep, ESMO Oct, WCL
Slide 51: Oncology Project Update
Dalichi-Sankyo Oncology Project Update 51
Slide 52: DS-8201: Clinical Program
ADC DS-8201: Clinical Program As of Apr 2018 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 Multiple Tumors Ph1 HER2+ mBreast DESTINY-Breast01 Post T-DM1 Pivotal Ph2 HER2+ mBreast Post T-DM1 Breast vs Phys Choice Ph3 Global HER2+ mBreast vs T-DM1 Ph3 HER2 low mBreast Ph3 HER2+ mGastric 3rd line vs DESTIN
Slide 53: DS-8201: Expand in mBC
ADC DS-8201: Expand in mBC Ph3 HER2+ mBreast Post T-DM1 vs Phys Choice Ph3 Primary endpoint: PFS Ph2 Secondary endpoint: OS DESTINY-Breast01 HER2+ mBreast ↓ Post T-DM1 Pivotal Ph2 Confirm overall survival Endpoint: ORR Plan to start from FY2018 Q2 BLA/MAA filing with results for Accelerated/Conditio
Slide 54: DS-8201: Target of BC Ph3 Under Preparation
ADC DS-8201: Target of BC Ph3 Under Preparation HR Receptor Sub Type HER2 IHC3+ ER PR HER2+ IHC2+/FISH+ Luminal A + + - HR+/HER2- HER2 IHC2+/FISH- Luminal B (HER2-) +/- weak+ /- - Low IHC1+/FISH- Luminal B (HER2+) + +/- + HER2- HER2+ HER2 - - + HER2- IHC0 TNBC Triple negative - - - HR+ Hormone thera
Slide 55: DS-8201: Clinical Program
ADC DS-8201: Clinical Program As of Apr 2018 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 Multiple Tumors Ph1 HER2+ mBreast DESTINY-Breast01 Post T-DM1 Pivotal Ph2 HER2+ mBreast Post T-DM1 vs Phys Choice Ph3 Breast Global HER2+ mBreast vs T-DM1 Ph3 HER2 low mBreast Ph3 HER2+ mGastric 3rd line vs DESTIN
Slide 56: DS-8201: Expand to New Indications
ADC DS-8201: Expand to New Indications Ph2: CRC Cohort A N=50 HER2 expressing IHC 3+ or IHC 2+/ISH + advanced colorectal cancer Cohort B N=20 Cohort B and C will be opened IHC 2+/ISH - depending on Endpoint: ORR the result of the Cohort C N=20 program IHC 1+ Started Mar 2018 Ph2: NSCLC HER2 overexpr
Slide 57: Oncology Future Data Disclosure
Oncology Future Data Disclosure Will hold conference call from ASCO to review details of presentation June 2, 2018, 9:00~10:00am (JST) June 2018 American Society of Clinical Oncology Abstracts available on May 16 DS-8201 June 1, Oral: Update of Ph1 including HER2 low BC Result of ILD adjudicat
Slide 58: Progress of 5-Year Business Plan
Progress of 5-Year Business Plan Grow Edoxaban Grow as No.1 Company in Japan Expand US Businesses Establish Oncology Business Continuously Generate Innovative Medicine Changing SOC (Standard of Care) Enhance Profit Generation Capabilities Shareholder Returns 58
Slide 59: DS Advancing in Regenerative Medicine / Cell Therapy
DS Advancing in Regenerative Medicine / Cell Therapy 2025 Vision Fulfill pipeline with innovative projects that change SOC* *SOC: standard of care Activities in 2016-2017 Strengthen our RD structure (established Cell Therapy Lab.) Explore seeds utilizing alliances and move forward to commerciali
Slide 60: KTE-C19: MOA and Japan Ph2 Study
KTE-C19: MOA and Japan Ph2 Study MOA Engineered T cells express antigen-specific CAR* on the cell surface. When CAR molecules recognize CD19 antigen on tumor cells, they transmit activation signals to T cells. Activated T cells release cytokines and show cytolytic activity against tumor cell
Slide 61: KTE-C19: Establishing Manufacturing Process for Launch
KTE-C19: Establishing Manufacturing Process for Launch Apheresis Manufacturing Process Infusion Collect Infuse patient Isolate and Engineer Grow and with engineered patient’s white activate T cell expand blood cells T cell T cells PMDA consultation to initiate clinical study in Japan has been comp
Slide 62: DS-5141: Ph1/2 Design and Summary of Result
DS-5141: Ph1/2 Design and Summary of Result Efficacy primary endpoint Dystrophin protein expression in muscle tissue(WB,IHC) Efficacy secondary endpoint Production of exon 45-skipped dystrophin mRNA in muscle tissue Part 1: Once a week x 2 Part 2: Once a week x 12 6 subjects (re-enter to Par
Slide 63: Progress of 5-Year Business Plan
Progress of 5-Year Business Plan Grow Edoxaban Grow as No.1 Company in Japan Expand US Businesses Establish Oncology Business Continuously Generate Innovative Medicine Changing SOC (Standard of Care) Enhance Profit Generation Capabilities Shareholder Returns 63
Slide 64: Enhance Profit Generation Capabilities
Enhance Profit Generation Capabilities Realize “Process Excellence”: Further cost reductions and streamlining FY2016 FY2017 Enhancement of procurement 13.2 Bn JPY 18.2 Bn JPY Target during 5YBP – 50.0 Bn JPY cost cost reductions cost reductions reductions for indirect materials*1 Optimization Sale o
Slide 65: Streamlining of Assets: Reduce Cross-Shareholding
Enhance Cash Flow Generation Capabilities: Streamlining of Assets Reduce Cross-Shareholding shares Reduce to the appropriate level from the point of view of capital efficiency FY2016 FY2017 Total Results Results Number of stocks 14 stocks 9 stocks 23 stocks Sales proceeds 17.3 Bn JPY 14.4 Bn JPY 3
Slide 66: Progress of 5-Year Business Plan
Progress of 5-Year Business Plan Grow Edoxaban Grow as No.1 Company in Japan Expand US Businesses Establish Oncology Business Continuously Generate Innovative Medicine Changing SOC (Standard of Care) Enhance Profit Generation Capabilities Shareholder Returns 66
Slide 67: Shareholder Returns
Shareholder Returns Shareholder Returns Policy during 5YBP* * 5YBP: 5-year Business Plan (FY2016 - FY2020) Annual Total return Ordinary dividend Flexible ratio more than acquisition of 100% 70 JPY own shares or more FY2016 FY2017 FY2018 (Target during Results Results Plan 5YBP) more than Dividend 70
Slide 68: FY2018 Consolidated Forecast
FY2018 Consolidated Forecast 68
Slide 69: FY2018 Consolidated Forecast
FY2018 Consolidated Forecast ( Bn JPY) FY2017 FY2018 YoY Results Forecast -5.2% Revenue 960.2 910.0 -50.2 Cost of Sales 346.0 330.0 -16.0 SG&A Expenses 301.8 292.0 -9.8 R&D Expenses 236.0 210.0 -26.0 +2.3% Operating Profit 76.3 78.0 +1.7 Profit before Tax 81.0 78.0 -3.0 -8.8% Profit attributable to
Slide 70: FY2018 Consolidated Forecast (excl. special items)
FY2018 Consolidated Forecast ( Bn JPY) FY2017 FY2018 Results YoY Impacts of patent Forecast (excl. special items) cliff Impact of price -5.2% revision in Japan Revenue 960.2 910.0 -50.2 36.1% 36.3% Decrease due to Cost of Sales 347.0 330.0 -17.0 revenue decrease Optimization in US SG&A Expen
Slide 71: Current Review of 5-Year Business Plan
Current Review of 5-Year Business Plan 71
Slide 72: Current Review of 5-Year Business Plan
Current Review of 5-Year Business Plan Edoxaban: Growing in momentum beyond the initial target Oncology: Accelerating toward 2025 Vison DS-8201, other ADCs and AMLs clinical trials are steadily progressing US Pain Business: Difficult to achieve the initial target Japan Business: Daunting b
Slide 73: Appendix
Appendix - R&D Milestone Events - Major R&D Pipeline - Out-licensing Projects - DS-8201 summary of conference presentation - Abbreviations 73
Slide 74: R&D Milestone Events
R&D Milestone Events As of Apr 2018 FY2017 FY2018 Project Indication / Study Q4 Q1 Q2 Q3 Q4 Pexidartinib Ph3: TGCT (US) Submission Quizartinib Ph3: QuANTUM-R AML2nd line treatment TLR Ph1: AML with Quizartinib Study initiation DS-3032 Ph1: AML with Azacitidine Study initiation Ph3: HER2+ Breast Post
Slide 75: Major R&D Pipeline
Major R&D Pipeline As of Apr 2018 Phase 1 Phase 2 Phase 3 Application DS-3032 (US/JP) U3-1402 (JP/US) Patritumab (EU) Denosumab (JP) (MDM2 inhibitor) (Anti-HER3 ADC) (U3-1287 / H&N cancer / Anti-HER3 antibody) (AMG 162 / Breast cancer adjuvant/ Anti- RANKL antibody) PLX7486 (US) DS-1001
Slide 76: Out-licensing Projects
Out-licensing Projects As of Apr 2018 Pre-clinical Phase1 Phase 2 Phase 3 DS-6051 (NTRK/ROS1 inhibitor) Oncology DS-1515 DS-2969 Laninamivir (Inflammatory disease/PI3Kδ (Clostridium difficile infection / (CS-8958/Anti-influenza/ Out- inhibitor) GyrB inhibitor) licensing with Vaxart Inc) Spec
Slide 77: DS-8201: HER2+ GC SAKIGAKE Designation
ADC DS-8201: HER2+ GC SAKIGAKE Designation SAKIGAKE designation in Mar 2018 For the treatment of HER2-positive advanced gastric or gastroesophageal junction cancer by the MHLW Gastric cancer treatment in Japan has high unmet medical needs and SAKIGAKE designation will help us accelerate the de
Slide 78: DS-8201: Ph1 Study Design
ADC DS-8201: Ph1 Study Design Dose escalation (Part 1) Dose expansion (Part 2) HNSTD Part 2-a HER2-positive T-DM1 pretreated BC Breast cancer or gastric/GEJ adenocarcinoma* 8.0 mg/kg Administered IV Q3W 3 pts Part 2-b RD HER2-positive 6.4 mg/kg Trastuzumab pretreated GC 6 pts RD 6 pts 5.4 mg/kg Part
Slide 79: DS-8201: Ph1 Efficacy
ADC DS-8201: Ph1 Efficacy Phase 1 | Any HER2-expressing tumor (n=165) HER2 Expression (IHC) 5.4 + 6.4 mg/kg 1+ 60 ORR=53% (88/165) 2+ 3+ NE* Best Change from Baseline (%) 40 Not Examined 20 0 -20 -40 -60 -80 -100 Tumor size shrinkage observed in most subjects As of Dec 2017 *NE: Not Evaluated(Same a
Slide 80: DS-8201: Ph1 Preliminary Efficacy
ADC DS-8201: Ph1 Preliminary Efficacy Breast PFS Median (months) - ORR Disease Control Rate (SABCS、Dec 2017) range HER2 positive All 61% (35/57) 95% (54/57) 10.4 (1.2+, 16.8+) HR Positive 56% (22/39) 92% (36/39) NR (1.2+, 16.8+) HR Negative 75% (12/16) 100% (16/16) 10.4 (1.2+, 14.1+) Prior pertuzuma
Slide 81: DS-8201: Ph1 Efficacy BC&GC
ADC DS-8201: Ph1 Efficacy BC&GC 1 year 40 % change in tumor size 20 Breast 0 HER2+ -20 -40 (SABCS, -60 Dec 2017) -80 -100 Weeks 10 20 30 40 50 60 70 80 20 % change in tumor size Breast 0 HER2 -20 Low -40 -60 (SABCS, -80 Dec 2017) Weeks -100 10 20 30 40 50 60 70 80 100 GC % change in tumor size 80 HE
Slide 82: DS-8201: Ph1 Preliminary Safety
ADC DS-8201: Ph1 Preliminary Safety Treatment-emergent events, any grade (>20%) All subjects with 5.4 or 6.4 mg/kg (N = 185, as of 15 Oct 2017) n (%) Preferred Term (MedDRA v18.0.) Grade 1 Grade 2 Grade 3 Grade 4 Any Hematologic Anaemia 14 (7.6) 22 (11.9) 25 (13.5) 2 (1.1) 63 (34.1) Platelet count d
Slide 83: Abbreviations
Abbreviations Abbreviation BTD Breakthrough therapy designation CR Complete response DCR Disease control rate DLT Dose limiting toxicity DOR Duration of response EGFR Epidermal growth factor receptor MTD Maximum tolerated dose NSCLC Non-small-cell lung cancer ORR Overall response rate Objective resp
Slide 84: Contact address regarding this material
Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126 Email: [email protected]
Daiichi Sankyo Company — FY2017 Earnings Presentation on 6ix